open access: Molecular Cancer | Role of Bcl-3 in solid tumors

"In this regard, it is interesting that, in addition to the known deregulation in leukemias and lymphomas, genome-wide expression studies have shown that Bcl-3 is overexpressed in breast cancer, glioblastoma tumors, ovarian cancer and, intriguingly, teratomas and embryonal> carcinomas (additional file 2). Although not validated, these results support the potential importance of this oncogene in a variety of tumors."

Role of Bcl-3 in solid tumors

Vilma Maldonado and Jorge Melendez-Zajgla

Molecular Cancer 2011, 10:152 doi:10.1186/1476-4598-10-152
Published: 23 December 2011

Abstract (provisional)

Bcl-3 is an established oncogene in hematologic malignancies, such as B-cell chronic lymphocytic leukemias. Nevertheless, recent research has shown that it also participates in progression of diverse solid tumors. The present review summarizes the current knowledge of Bcl3 role in solid tumors progression, including some new insights in its possible molecular mechanisms of action

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

open access: Whole Genome Sequences of a Male and Female Supercentenarian, Ages Greater than 114 Years | Frontiers in Genetics of Aging

Why Some People Live to 110 - Drugs.com MedNews

"......In what they describe as a first-of-a-kind study, the researchers analyzed the whole genome sequences of a man and a woman who lived past the age of 114 and found that they had as many disease-associated genes as other people.
For example, the man had 37 genetic mutations associated with increased risk for colon cancer....."

Jan 8th - Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products... -- Excedrin, NoDoz, Bufferin, Gas-X Prevention

PARSIPPANY, N.J., Jan. 8, 2012 /PRNewswire/ -- Novartis Consumer Health, Inc. (NCH) announced today that it is voluntarily recalling all lots of select bottle packaging configurations of Excedrin^® and NoDoz^® products with expiry dates of December 20, 2014 or earlier as well as Bufferin^® and Gas-X Prevention^® products with expiry dates of December 20, 2013 or earlier, in the United States. NCH is taking this action as a precautionary measure because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets...........

open access Frontiers | Epigenomics of Ovarian Cancer and Its Chemoprevention | Frontiers in Epigenomics

.......Due to the atypical syndrome of the early stage of ovarian cancer, it is difficult to diagnose in its early stages. By the time most ovarian cancers are diagnosed, they are already at stage III or IV. The two most significant obstacles to the effective treatment of ovarian cancers are the lack of early diagnostic markers and the development of drug resistance after therapeutic treatment of advanced disease. Ovarian cancer screening with transvaginal ultrasound (TVU) and CA125 was evaluated in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial, however, it was revealed that the predictive value of both tests was relatively low (Buys et al., 2005). Increasing evidence indicates that epigenetic mechanisms may play a major role in the development of ovarian cancer..........
In this analysis, we will evaluate the current status of epigenomics of ovarian cancer and will include epigenetic mechanisms involved in ovarian cancer development such as DNA methylation, histone modifications, and non-coding microRNA. Development of biomarkers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer will also be assessed. In addition, the potential use of natural compounds as epigenetic modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer treatment strategies........

open access journal: Frontiers | Grand Challenges in Oncology | Frontiers in Oncology

Frontiers in Oncology

This new open access journal has one of the major goals to be the forum for publications in the most important areas of cancer research, spanning from diagnosis, and prevention to treatment of early and advanced cancer and drug development, to the most cutting edge technologies that can be implemented to study cancer and improve its treatment. The fast pace of research and its ever increasing scope and breath, require a comprehensive forum that allows both the depth of research and a broad readership. This will be accomplished by a large series of subspecialties within Frontiers in Oncology, which span the major areas of disease-oriented research, epidemiology and prevention, treatment, and basic research.

open access: A person-time analysis of hospital activity among cancer survivors in England - UKPMC Article - UK PubMed Central

Conclusion:

The person-time approach used in this study is more revealing than a simple enumeration of cancer survivors and hospital admissions. Hospital activity among cancer survivors is highest soon after diagnosis. The effect of age on the amount of hospital activity is different for each type of cancer.

...........This paper highlights the significant effect that time since diagnosis has on the average amount of hospitalisation experienced by cancer survivors. The majority of cancer-related admitted hospital episodes of care occurred in the first year following diagnosis (when initial cancer treatment takes place); however, there was also a significant amount of hospital activity in the period 1–5 years after diagnosis, particularly among survivors of colorectal and lung cancers, which is indicative of the ongoing consequences of cancer and its treatment. Other work has shown that the final year before death also contains significant amounts of hospitalisation of cancer survivors (Maddams et al, 2011). These findings help to understand the burden of cancer on the health service, but further work is still required to identify potential areas of unmet needs among cancer survivors.

open access: Fruit and vegetables and cancer risk - UKPMC Article - UK PubMed Central

Blogger's note: the article/reference(s) does not include ovarian cancer research on this issue

The possibility that fruit and vegetables may help to reduce the risk of cancer has been studied for over 30 years, but no protective effects have been firmly established..........

blog: An Update to 23andMe Customers